Andere Sprachen Belite Bio, Inc

Aktien

A3DKYL

US07782B1044

BLTE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 29.04.2024			% 5 Tage	% 1. Jan.
40,93 ^USD	+2,97 %		+18,71 %	-10,54 %

26.04.	Belite Bio stellt Plan zum Angebot von 651.380 American Depository Shares vor	MT
22.03.	Belite Bio schließt Zulassungsantrag für die klinische Studie von Tinlarebant in Japan ab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Belite Bio Unveils Plan to Offer 651,380 American Depository Shares	26.04.
Belite Bio Announces $25 Million Registered Direct Offering	26.04.
Belite Bio : Initiates Stargardt Disease Clinical Trial in Japan	22.04.
Belite Bio : Announces MHRA Submission of Tinlarebant for Stargardt Disease Clinical Trial in the United Kingdom	18.04.
Belite Bio : Submits US IND Amendment to Initiate a Phase 2/3 Clinical Trial of Tinlarebant in Stargardt Disease	25.03.
Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan	22.03.
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22.03.
Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	22.03.
ADRs End Higher, ATRenew Inc. Climbs 26.9%	12.03.
Belite Bio's Q4 Loss Narrows	12.03.
Belite Bio, Inc Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Belite Bio, Inc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website	12.03.
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	12.03.
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results	06.03.
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results	06.03.
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference	04.03.
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference	04.03.
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07.02.
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Belite Bio, Inc

Aktien

A3DKYL

US07782B1044

BLTE

Andere Sprachen

Filter